JSE-listed pharmaceutical group Aspen Pharmacare Holdings has agreed to various commitments to address competition concerns raised by the European Commission after it opened an investigation into Aspen and some of its European subsidiaries. The commission believes Aspen may have abused its dominant position by imposing unfair prices on molecules – or products, including chlorambucil, melphalan, mercaptopurine, tioguanine and busulfan, sold in the European Economic Area (EEA).
from Engineering News | Home https://ift.tt/3j0vm7m
